Please login to the form below

Not currently logged in
Email:
Password:

UCB launches epilepsy campaign

UCB has launched 'Epilepsy In Our Time' – a video campaign to mark the first European Epilepsy Day

UCB has launched 'Epilepsy In Our Time' – a video campaign to mark the first European Epilepsy Day.

The annual event is co-ordinated by the International Bureau for Epilepsy (IBE), an organisation comprising epilepsy associations from across the world, and the International League Against Epilepsy (ILAE), a global organisation representing healthcare professionals working in the field of epilepsy.

It is scheduled to be held each year on the second Monday in February, with plans to raise awareness of the condition across Europe.

UCB's campaign involves online video diaries made by people living with epilepsy. The company said the diaries provide an insight into modern perceptions of the condition, as well as what epilepsy is like to live with.

People involved in the series of videos include Marion, who won an Olympic silver medal in cycling for France in 2000, and Julie and David, whose 11-year-old son Dominic has severe epilepsy.

UCB has launched 'Epilepsy In Our Time'


Commenting on the 'Epilepsy In Our Time' campaign, Mike Glynn, president, IBE, said: "Epilepsy is the most common serious brain disorder, affecting 6 million people in Europe, but is an under-recognised and poorly understood condition, often leaving individuals exposed to stigma and prejudice. We welcome any new initiative that raises awareness and understanding of epilepsy."

European Epilepsy Day follows the annual Latin American Epilepsy Day held on September 9, with the IBE saying it plans to hold an annual day in each of its seven regions.

Plans for an international epilepsy day have been postponed until the World Health Organization is able to offer its support, according to the IBE.

Belgium-based biopharma UCB specialises in developing therapies for severe central nervous system or immunological disorders, and has several epilepsy drugs approved for marketing, including Vimpat (lacosamide) and Keppra (levetiracetam).

14th February 2011

Share

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Frontera Group

A leading global patient-activation group - comprising of a digital insight consultancy, creative activation agency. Our foundations lie in behavioural...

Latest intelligence

dementia
Alzheimer’s Research UK highlights socio-economic inequalities in dementia risk
The charity aims to improve the number of women participating in dementia research and grow awareness of dementia risk factors...
Data security
Concerns about data security are building a strong case for clinical mobility in EMEA
Electronic medical records have transformed the storage of sensitive information but how can the healthcare sector continue to protect patient and staff data?...
Mainimage2
The role of digital health technology tools in supporting medical adherence
How DHT-based digital interventions can help to support patients and improve adherence...